Article
Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Cell reports - 30 May 2017
Calvert Andrea E, Chalastanis Alexandra, Wu Yongfei, Hurley Lisa A, Kouri Fotini M, Bi Yingtao, Kachman Maureen, May Jasmine L, Bartom Elizabeth, Hua Youjia, Mishra Rama K, Schiltz Gary E, Dubrovskyi Oleksii, Mazar Andrew P, Peter Marcus E, Zheng Hongwu, James C David, Burant Charles F, Chandel Navdeep S, Davuluri Ramana V, Horbinski Craig, Stegh Alexander H
Abstract excerpt
Oncogenic mutations in two isocitrate dehydrogenase (IDH)-encoding genes (IDH1 and IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and secondary glioblastoma (GBM). Our in silico and wet-bench analyses indicate that non-mutated IDH1 mRNA and protein are commonly overexpressed in primary GBMs. We show that genetic and pharmacologic inactivation of IDH1 decreases GBM cell growth,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.